Combined therapy for Alzheimer's disease
https://doi.org/10.14412/2074-2711-2022-3-74-80
Abstract
Alzheimer's disease (AD) is the most common cause of cognitive impairment and dementia. A non-systematic review of literature is presented, which discusses the clinical features and current criteria for diagnosis of this disease. The review presents classifications of cognitive impairments, including severity, as well as diagnostic criteria for various stages of dementia. The main approaches to the management of patients with dementia in AD as the disease progresses are highlighted. Modern publications dedicated to the problem of combined therapy of dementia in AD with donepezil and memantine are considered. The fixed combination of these drugs in a single tablet once daily regimen has been shown to provide significant benefits over acetylcholinesterase inhibitor monotherapy, especially in patients with dysphagia, poor adherence to treatment and limited interaction with caregivers.
Keywords
Supporting agencies: This article has been supported by Novamedica.
About the Authors
V. V. Zakharov
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
Department of Nervous Diseases and Neurosurgery
11, Rossolimo St., Build. 1, Moscow 119021
A. V. Lokshina
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
Department of Nervous Diseases and Neurosurgery
11, Rossolimo St., Build. 1, Moscow 119021
N. V. Vakhnina
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
Department of Nervous Diseases and Neurosurgery
11, Rossolimo St., Build. 1, Moscow 119021
References
1. Parfenov VA, Zaharov VV, Preobrazenskaya IS. Kognitivnyye rasstroystva [Cognitive impairment]. Moscow; 2014. 192 p. (In Russ.).
2. Yakhno NN, Zakharov VV, Lokshina AB, et al. Dementsii. Rukovodstvo dlya vrachey [Dementia. Guidance for doctors]. Moscow: MEDpressinform; 2011. P. 17-28. Available from: https://www.03book.ru/upload/iblock/987/415_Demencija_Jahno.pdf (accessed 30.05.2020) (In Russ.).
3. Parfenov VA. Alzheimer's disease: clinical management errors. Meditsinskiy sovet = Medical Council. 2020;(19):23-8. doi: 10.21518/2079-701X-2020-19-23-28 (In Russ.).
4. 2016 Alzheimer's disease facts and figures. Alzheimer's Association. Alzheimers Dement. 2016 Apr;12(4):459-509. doi: 10.1016/j.jalz.2016.03.001
5. Germain S, Adam S, Olivier C, et al. Does cognitive impairment influence burden in caregivers of patients with Alzheimer's disease? J Alzheimers Dis. 2009;17(1):105-14. doi: 10.3233/JAD-2009-1016
6. Eikelboom WS, van den Berg E, Singleton EH, et al. Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum: Cross-sectional and Longitudinal Associations. Neurology. 2021 Sep 28;97(13):e1276-e1287. doi: 10.1212/WNL.0000000000012598. Epub 2021 Aug 19.
7. Zhao QF, Tan L, Wang HF, et al. The prevalence of neuropsychiatric symptoms in Alzheimer's disease: Systematic review and meta-analysis. J Affect Disord. 2016 Jan 15;190:264-71. doi: 10.1016/j.jad.2015.09.069. Epub 2015 Oct 24.
8. Lokshina AB, Zakharov VV, Grishina DA, et al. Heterogeneity of the mild cognitive impairment syndrome (specialized outpatient service data analysis). Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2021;13(3):34-41. doi: 10.14412/2074-2711-2021-3-34-41 (In Russ.).
9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Diseases. Fifth Edition (DSM-V). London; 2013. Available from: https://www.psychiatry.org/psychiatrists/practice/dsm
10. Dementia. Comprehensive Principles and Practice. Oxford University Press; 2014. P. 377-83, 432-48. doi: 10.1093/med/9780199928453.001.0001
11. Lokshina AB. Management of patients with demension: holinergic deficiency and its correction. Meditsinskiy sovet = Medical Council. 2018;(12):30-5. doi: 10.21518/2079-701X-2018-12-30-35 (In Russ.).
12. Lokshina AB, Grishina DA. Treatment of noncognitive neuropsychiatric disorders in Alzheimer's disease. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2021;13(6):132-8. doi: 10.14412/2074-2711-2021-6-132-138 (In Russ.).
13. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimers Dement. 2011;5:263-9. doi: 10.1016/j.jalz.2011.03.005
14. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May;7(3):270-9. doi: 10.1016/j.jalz.2011.03.008. Epub 2011 Apr 21.
15. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimers Dement. 2011 May;7(3):280-92. doi: 10.1016/j.jalz.2011.03.003. Epub 2011 Apr 21.
16. Jack CR Jr, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May;7(3):257-62. doi: 10.1016/j.jalz.2011.03.004. Epub 2011 Apr 21.
17. Dubois B, Feldman H, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010 Nov;9(11):1118-27. doi: 10.1016/S1474-4422(10)70223-4. Epub 2010 Oct 9.
18. Chiong W, Tolchin BD, Bonnie RJ, et al; on behalf of the Ethics, Law, and Humanities Committee (a joint committee of the AAN, ANA, and CNS). Decisions With Patients and Families Regarding Aducanumab in Alzheimer Disease, With Recommendations for Consent: AAN Position Statement. Neurology. 2022;98(4):154-9. doi: 10.1212/WNL.0000000000013053
19. Decourt B, Boumelhem F, Pope ED 3rd, et al. Critical Appraisal of Amyloid Lowering Agents in AD. Curr Neurol Neurosci Rep. 2021 Jun 10;21(8):39. doi: 10.1007/s11910-021-01125-y
20. Chalfont G, Milligan C, Simpson J. A mixed methods systematic review of multimodal non-pharmacological interventions to improve cognition for people with dementia. Dementia (London). 2020;19(4):1086-130. doi: 10.1177/1471301218795289
21. McShane R, Westby MJ, Roberts E, et al. Memantine for dementia. Cochrane Database Syst Rev. 2019 Mar 20;3(3):CD003154. doi: 10.1002/14651858.CD003154.pub6
22. Mendiola-Precoma J, Berumen LC, Padilla K, Garcia-Alcocer G. Therapies for Prevention and Treatment of Alzheimer's Disease. Biomed Res Int. 2016;2016:2589276. doi: 10.1155/2016/2589276. Epub 2016 Jul 28.
23. Kishi T, Matsunaga S, Iwata N. The effects of memantine on behavioral disturbances in patients with Alzheimer's disease: a metaanalysis. Neuropsychiatr Dis Treat. 2017 Jul 20;13:1909-28. doi: 10.2147/NDT.S142839. eCollection 2017.
24. Deardorff WJ, Grossberg GT. A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-tosevere Alzheimer's disease. Drug Des Devel Ther. 2016 Oct 3;10:3267-79. doi: 10.2147/DDDT.S86463. eCollection 2016.
25. Chen Y, Dang M, Zhang Z. Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer's disease: a systematic review of symptom-general and -specific lesion patterns. Mol Neurodegener. 2021 Jun 7;16(1):38. doi: 10.1186/s13024-021-00456-1
26. Boinpally R, Chen L, Zukin SR, et al. A novel once-daily fixed-dose combination of memantine extended release and donepezil for the treatment of moderate to severe Alzheimer's disease: two phase I studies in healthy volunteers. Clin Drug Investig. 2015 Jul;35(7):427-35. doi: 10.1007/s40261-015-0296-4
27. Guo J, Wang Z, Liu R, et al. Memantine, Donepezil, or Combination Therapy-What is the best therapy for Alzheimer's Disease? A Network Meta-Analysis. Brain Behav. 2020 Nov;10(11):e01831. doi: 10.1002/brb3.1831. Epub 2020 Sep 10.
28. Calhoun A, King C, Khoury R, Grossberg GT. An evaluation of memantine ER + donepezil for the treatment of Alzheimer's disease. Expert Opin Pharmacother. 2018 Oct;19(15):1711-7. doi: 10.1080/14656566.2018.1519022. Epub 2018 Sep 23.
29. Smolyarchuk EA, Leykin ZN. Comparative clinical study of the pharmacokinetics and bioequivalence of the combined drug Mioreol® and the combined use of monopreparations containing donepezil and memantine. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2022;122(4) (in press) (In Russ.).
Review
For citations:
Zakharov VV, Lokshina AV, Vakhnina NV. Combined therapy for Alzheimer's disease. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2022;14(3):74-80. (In Russ.) https://doi.org/10.14412/2074-2711-2022-3-74-80
Views:
575
Email this article 